Newron Pharmaceuticals

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By targeting the hippocampus region of the brain, evenamide addresses schizophrenia at the source of dysfunction. 3 February 2026 -- Milan, Italy and New Jersey, US -- Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused...

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling at least 1,000 schizophrenia patients with topline results expected in Q4-2026 Evenamide is a first-in-class glutamate modulator with a novel mechanism of action for patients...
via Antonio Meucci 3 20091 Bresso (Mi) Italy

+39 02 610 3461